Korean J Obstet Gynecol Search

CLOSE


Obstet Gynecol Sci > Volume 55(11); 2012 > Article
Korean Journal of Obstetrics & Gynecology 2012;55(11):814-821.
DOI: https://doi.org/10.5468/KJOG.2012.55.11.814    Published online November 16, 2012.
Synergistic effects of sorafenib and celecoxib inhibit growth and VEGF expression in Hec-1A endometrial cancer cell line.
Jeong Sig Kim, Bo Ra Park, Gye Hyun Nam, Dong Han Bae
1Department of Obstetrics and Gynecology, Soonchunhyang Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea. jskim@schmc.ac.kr
2Department of Obstetrics and Gynecology, Soonchunhyang Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.
3Department of Obstetrics and Gynecology, Soonchunhyang Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
Abstract
OBJECTIVE
The aim of this study was to investigate whether combination of sorafenib and celecoxib exhibited an anti-tumor efficacy or altered expression of vascular endothelial growth factor (VEGF) in Hec-1A endometrial cancer cell line. METHODS: To determine whether sorafenib or celecoxib-induced growth inhibition was determined by the (3-[4,5-dimethylthiazol-2-yl]-5-[3-carboxymethoxyphenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt) assay. Expression of VEGF and p53 were evaluated using the reverse transcription polymerase chain reaction. RESULTS: Combination of sorafenib 10 ng/mL and celecoxib 50 micromol/L exhibited synergistic inhibitory effects compared to treatment with each agent alone (P<0.0001). VEGF expression was also down regulated after 24 hours or 72 hours of treatment with sorafenib alone or in combination with sorafenib and celecoxib in Hec-1A cells. However, there was no alteration of p53 expression in Hec-1A cells after 24 hours or 72 hours of treatment with sorafenib alone or in combination with sorafenib and celecoxib. CONCLUSION: Combination treatment of sorafenib and celecoxib to Hec-1A endometrial cancer cell line revealed the ability to inhibit growth and expression of VEGF.
Key Words: Endometrial cancer, Sorafenib, Celecoxib, Vascular endothelial growth factor


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
POLICY
FOR CONTRIBUTORS
Editorial Office
4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea
Tel: +82-2-3445-2382    Fax: +82-2-3445-2440    E-mail: journal@ogscience.org                

Copyright © 2020 by Korean Society of Obstetrics and Gynecology. All rights reserved.

Developed in M2community

Close layer
prev next